Q32, Horizon announce dosing of first patient in Phase 2 Bempikibart trial

Q32 Bio and Horizon Therapeutics (HZNP) announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata. Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Ralpha antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways. “Dosing of the first patient in the Phase 2 study in alopecia areata, in addition to our ongoing Phase 2 study in atopic dermatitis, demonstrate the breadth of potential applications of bempikibart and our deep commitment to transform the lives of patients with autoimmune and inflammatory diseases,” said Jodie Morrison, acting CEO, Q32 Bio. “Q32 Bio and Horizon are mutually dedicated to advancing bempikibart expeditiously through both Phase 2 studies.”